Oppenheimer Maintains Outperform on Biogen, Lowers Price Target to $290
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Jay Olson has maintained an 'Outperform' rating on Biogen (NASDAQ:BIIB) but lowered the price target from $360 to $290.
August 07, 2023 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biogen's price target has been lowered from $360 to $290 by Oppenheimer, though the 'Outperform' rating is maintained.
The lowering of the price target by Oppenheimer could lead to a short-term negative impact on Biogen's stock price as it indicates a lower expected future value. However, the maintained 'Outperform' rating suggests that the analyst still expects the stock to outperform its peers.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100